These novel therapies , Semaglutide , represent a remarkable advancement in addressing obesity and possibly associated conditions . They all are grouped as GLP-1 pathway agonists , meaning they to emulate the natural GLP-1 peptide, enhancing glucose production and suppressing hunger . Although Ti